期刊
CURRENT ONCOLOGY REPORTS
卷 18, 期 4, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-016-0509-x
关键词
Immunotherapy; Checkpoint blockade; Ipilimumab; Nivolumab; Pembrolizumab; Biomarkers; PD-1; PD-L1; CTLA-4; Neoantigens; Melanoma
类别
资金
- Bristol-Myers Squibb
The immune system plays an essential role in the surveillance and eradication of neoplastic cells. This interaction is modulated via immunologic regulators (checkpoints). Antibodies that block the checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the programmed cell death protein 1 pathway (PD1/PD-L1) have demonstrated efficacy in a number of malignancies. However, response rates are variable, and administration of these antibodies can be associated with immune-related adverse events. Therefore, researchers are engaged in an effort to discover biomarkers that may predict response to these agents. This review focuses on potential blood and tumor-based biomarkers that have been assessed in patients treated with these checkpoint-blocking antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据